Accelerating paediatric formulation development through smart design and predictive science

Lead Participant: ASTRAZENECA UK LIMITED

Abstract

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

Lead Participant

Project Cost

Grant Offer

ASTRAZENECA UK LIMITED £147,777 £ 73,889
 

Participant

GLAXOSMITHKLINE SERVICES UNLIMITED £141,918 £ 70,959
UNIVERSITY OF BATH £92,000 £ 92,000
JUNIPER PHARMA SERVICES LIMITED £100,294 £ 60,176
ASTON UNIVERSITY £14,520 £ 14,520
UNIVERSITY COLLEGE LONDON
UNIVERSITY OF BIRMINGHAM £90,704 £ 90,704
UNIVERSITY COLLEGE LONDON £102,018 £ 102,018
PFIZER LIMITED £150,469 £ 75,235
ACADEMY OF PHARMACEUTICAL SCIENCES £6,218 £ 3,731
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED £146,742 £ 73,371

Publications

10 25 50